Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
71.24
-0.61 (-0.85%)
At close: Jun 18, 2025, 4:00 PM
71.00
-0.24 (-0.34%)
After-hours: Jun 18, 2025, 6:03 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,370,892
Profits / Employee
$265,014
Market Cap
7.55B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CORT News
- 6 days ago - Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring - Seeking Alpha
- 8 days ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 14 days ago - Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - Business Wire
- 17 days ago - Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 6 weeks ago - Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Business Wire
- 7 weeks ago - CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
- 2 months ago - CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire